Druggist body to float consultancy firm

Image
Maulik PathakIla Parikh Mumbai/ Ahmedabad
Last Updated : Feb 05 2013 | 3:55 AM IST
The All India Chemist and Druggist Association (AIOCD) is rolling up its sleeves to set up a pharma consultancy and data gathering firm on the lines of ORG-IMS Research.
 
AIOCD has tied up with Chennai-based Trikaal Medi Infotech and formed a new entity called Advanced Working Action and Collection System or AWACS meaning radar.
 
"In the next three years, we expect AWACS to have a revenue generation of Rs 250-300 crore. We are in talks with various consultancy firms for research and analysis," a senior AIOCD official told Business Standard. This also includes Ernst & Young and Accenture, who were advisers to AIOCD when it got corporatised.
 
AWACS has been working on the project for the last one year. So far, it has covered 14 states. In India, ORG-IMS data is the only firm that comes up with a monthly report on the pharma industry with in-depth analysis and research. Most of the leading pharma companies rely on ORG.
 
"We will roll-out the project commercially from June-July this year covering pharma data of all Indian states. Next week, we are launching a pre-trial of our collected data for three months wherein we will send our reports to major pharma companies for verification," said Amish Masudekar, director of AWACS.
 
AWACS has so far spent about Rs 10 crore for the project. "AIOCD has a strong chain of 550,000 members across the country and 150,000 wholesalers. We have been providing data to ORG all these years. This time, we thought of doing it on our own and this will add to our income too," said Jashvant Patel, president, Federation of Gujarat State Chemists and Druggists.
 
JS Shinde, honorary general secretary of AIOCD is the chairman of AWACS while Samshir Sheikh of Trikaal Medi Infotech is the CEO.
 
Patel said there would be a marked difference between ORG and AWACS data and it was for the industry to figure out which one they would want to go with. He cited an example of a Gujarat-based pharma major, which according to ORG had shown a 25 per cent growth but grew only 0.6 per cent according to AWACS.

 

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 01 2008 | 12:00 AM IST

Next Story